FOLFOX方案化疗联合参麦注射液在治疗结直肠癌术后患者的临床疗效分析
|
摘要
目的:研究FOLFOX方案化疗联合参麦注射液在治疗结直肠癌术后患者的临床疗效。方法:选取2015年3月-2017年3月来我院就诊的40例术后适合化疗的癌症患者作为研究对象,通过随机分组的方式分为对照组和实验组,每组各20例,对照组患者采取FOLFOX方案化疗,实验组患者在此基础上配合参麦注射液治疗,对比两组患者的临床疗效、不良反应的发生率。结果:实验组患者的临床疗效明显优于对照组患者,并且其不良反应的发生率明显低于对照组患者,P <0.05。结论:相较于单独使用FOLFOX方案化疗,FOLFOX方案化疗联合参麦注射液可以更好地治疗结直肠癌术后患者,提高患者的临床疗效,降低患者的不良反应发生率,可以帮助患者更好地恢复身体健康,因此值得被推广。
Objective: To investigate clinical efficacy of FOLFOX chemotherapy plus the Shenmai injection( 参麦注射液) on postoperative colorectal cancer patients. Methods: From March 2015 to March 2017, 40 cases were divided into two groups, 20 cases in each. The control group was given FOLFOX chemotherapy simply; and the experimental group was given the Shenmai injection more.Results: Clinical efficiency in the experimental group was better, and the incidence of adverse reactions was lower, P<0.05. Conclusion:FOLFOX chemotherapy plus the Shenmai injection on postoperative colorectal cancer shows a good effect, with less adverse reactions, and is worthy of promotion.
Objective: To investigate clinical efficacy of FOLFOX chemotherapy plus the Shenmai injection( 参麦注射液) on postoperative colorectal cancer patients. Methods: From March 2015 to March 2017, 40 cases were divided into two groups, 20 cases in each. The control group was given FOLFOX chemotherapy simply; and the experimental group was given the Shenmai injection more.Results: Clinical efficiency in the experimental group was better, and the incidence of adverse reactions was lower, P<0.05. Conclusion:FOLFOX chemotherapy plus the Shenmai injection on postoperative colorectal cancer shows a good effect, with less adverse reactions, and is worthy of promotion.
引文
[1]汤海波.FOLFOX4联合参麦注射液治疗中晚期肝癌术后存活质量的影响[J].肝胆外科杂志,2016,24(6):448-452.
[2]马红英,赵径.化疗联合参麦注射液治疗消化系统恶性肿瘤的临床观察[J].医学信息,2015,28(8):83-84.
[3]魏荣富,金茂勇.参麦注射液联合TP化疗方案对乳腺癌术后患者的疗效观察及生存质量的影响[J].实用癌症杂志,2016,31(7):1088-1090.
[4]李芹,陈曦.参麦注射液联合化疗治疗晚期恶性肿瘤的疗效分析[J].黑龙江医学,2014,38(9):1023-1024.
[5]刘学梅,段世玲,刘勇峰,等.参麦注射液联合化疗治疗进展期胃癌29例[J].河南中医,2015,35(9):2285-2287.
[2]马红英,赵径.化疗联合参麦注射液治疗消化系统恶性肿瘤的临床观察[J].医学信息,2015,28(8):83-84.
[3]魏荣富,金茂勇.参麦注射液联合TP化疗方案对乳腺癌术后患者的疗效观察及生存质量的影响[J].实用癌症杂志,2016,31(7):1088-1090.
[4]李芹,陈曦.参麦注射液联合化疗治疗晚期恶性肿瘤的疗效分析[J].黑龙江医学,2014,38(9):1023-1024.
[5]刘学梅,段世玲,刘勇峰,等.参麦注射液联合化疗治疗进展期胃癌29例[J].河南中医,2015,35(9):2285-2287.